Impact of blood p-tau217 testing on diagnosis and diagnostic confidence in cognitive disorders: a real-world clinical study - PubMed
3 months ago
- #Biomarkers
- #Diagnostic accuracy
- #Alzheimer’s disease
- Blood biomarker p-tau217 improves diagnostic accuracy and confidence in Alzheimer's disease (AD) pathology.
- Study involved 200 patients with cognitive symptoms in general neurology and memory unit settings.
- 25.5% of patients had a change in diagnostic category post p-tau217 testing.
- Diagnostic confidence significantly increased from 6.90 to 8.49 after receiving p-tau217 results.
- Post-biomarker diagnosis was maintained in 94.5% of cases, showing high accuracy.
- P-tau217 testing is feasible and impactful in real-world clinical settings across all stages of cognitive decline.